Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 15, Issue 5 (September 2013) 15, 586–587; 10.1038/aja.2013.82

Somatic DNA copy number alterations and their potential clinical utility for predicting lethal prostate cancer

Wennuan Liu1,2, Li Wang1,2 and Jianfeng Xu1,2,3

1 Center for Cancer Genomics, Winston-Salem, NC 27157, USA
2 Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
3 Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China

Correspondence: Dr JF Xu, (jxu@wfubmc.edu)

advance online publication, July 1, 2013

Abstract

Current clinicopathologic indicators are insufficient to distinguish the small percentage of aggressive prostate cancer (PCa) from the vast majority of indolent disease at diagnosis, leading to overtreatment of PCa. A recent study reported and confirmed a strong association of PCa-specific mortality with somatic DNA copy number alterations (CNAs) in primary prostate tumors. If a sensitive, robust and low-cost method can be developed to measure these CNAs in biopsy specimens, it may help to stratify patients for more appropriate management at the time of diagnosis; aggressive treatment or active surveillance for patients with or without these CNAs, respectively.

PDF |

 
Browse:  275
Copyright 1999-2014    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved